You are here

Home » Content

CYTOTOXICITY EFFECT OF NANO-ENGINEERED CARRIERS ENCAPSULATING CHEMOTHERAPEUTIC DRUG ON HUMAN COLORECTAL ADENOCARCINOMA CELL

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
Intense research has led to a more comprehensive understanding of cancer at the genetic, molecular and cellular levels providing a possibility for methods of increasing antitumor efficiency of drugs while reducing systemic side effects. Nanoparticles and their use in drug delivery is a far more effective antitumor method conventional chemotherapy, which is typically limited by the toxicity of drugs to normal tissues, short circulation half in plasma, limited aqueous solubility, and non restricting therapeutic efficacy. The use of conventional chemotherapy is hampered due to obstacles such as poor specificity, side effects, drug resistance and poor stability of chemotherapeutic compounds. These obstacles may be partially overcome by encapsulating them as Solid lipid Nanoparticles (SLN). Measures of anti-carcinogenic potential of the nano-engineered formulations were investigated using cultured carcinoma cells. Evaluation of anti potential by Annexin-V-FITC/PI apoptosis assay following 48 h treatment with SLN and native drugs delineated sign differences, establishing better potential efficacy of nano engineered drugs.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon 9-18-40-ijprbs-168.16.pdf
  • 5
250-260
  • English

REFERENCES

References: 

1. Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun M J: Cancer statistics, CA Cancer J
Clin. 2007; 57: 43.
2. Adiga S M, Kumari M K, Bairy K L, Mohan
Babu A, Vadiraja B M and Vidyasagar M S:
The effect of using combination
chemotherapy in colorectal cancer in India:
A single institute survey, Cancer Res Exp
Oncol, 2010; 2: 001.
3. Hill M J, Morsan B C and Bussey H J:
Aetiology of adenoma-carcinoma sequence
in large bowel, Lancet. 1978; 1: 245.
4. Albet D S: Reducing the risk of colorectal
cancer by intervening in the process of
carcinogenesis: a status report, Cancer J.
2002; 8: 208.
5. Frei E III and Antman K H: Combination
chemotherapy, dose, and schedule, in
Cancer Medicine. 1997: 817.
6. Douillard J Y, Cunningham D and Roth A
D: Irinotecan combined with fluorouracil
compared with fluorouracil alone as firstline
treatment for metastatic colorectal
cancer: a multicentre randomised trial,
Lancet. 2000; 355: 1041.
7. Saltz L B, Cox J V and Blanke C: Irinotecan
plus fluorouracil and leucovorin for
metastatic colorectal cancer, N Engl J Med.
2000: 905.
8. Kulig J, Popiela T, Richter P and Klek S:
Evaluation adjuvant chemotherapy
irinotecan + 5 fluorouracil + leucovorin in
advanced colorectal cancer, Acta Cher Belg.
2007; 107: 297.
9. Tournigand C, Andre T, Achille E, Lledo G,
Flesh M and Merymignard D: FOLFIRI
followed by FOLFOX6 or the reverse
sequence in advanced colorectal cancer: a
randomized GERCOR study, J Clin Oncol.
2004; 22: 229.
10. Hwang J J, Eisenberg S G and Marshall J
L: Improving the toxicity of irinotecan/5-
FU/leucovorin: a 21-day schedule,
Oncology. 2003; 17: 37.
11. Douillard J Y: Irinotecan and high-dose
fluorouracil/leucovorin for metastatic
colorectal cancer, Oncology. 2000; 14: 51.
12. Magrath I T: Targeted approaches to
cancer therapy, Int J Cancer. 1994; 56: 163.
REFERENCES
Research Article ISSN: 2277-8713
Sourabh Tiwari, IJPRBS, 2012; Volume 1(5): 250-260 IJPRBS
Available Online At www.ijprbs.com
13. Pal D K and Nayak A K: Nanotechnology
For Targeted Delivery In Cancer
Therapeutics, Int J Pharm Sci Rev Res.
2010; 1: 1.
14. Li C: Poly (L-glutamic acid)–anticancer
drug conjugates, Adv Drug Deliv Rev. 2002;
54: 695.
15. Praetorius N P and Mandal T K:
Engineered Nanoparticles in Cancer
Therapy, Recent Pat Drug Deliv Formul.
2007; 1: 37.
16. Medina C, Santos-Martinez M J,
Radomski A, Corrigan O I & Radomski M W,
Nanoparticles: pharmacological and
toxicological significance, Bri J Pharm, 150
(2007) 552.
17. Ravi Kumar M N V: Nano and
microparticles as controlled drug delivery
devices, J Pharm Pharmaceut Sci. 2000; 3:
234.
18. Jain P, Mishra A, Yadav S K, Patil U K and
Baghel U S: Formulation Development and
Characterization of Solid Lipid Nanoparticles
Containing Nimesulide, Int J Drug Deliv
Tech. 2009; 1: 24.

Thank you for copying data from http://www.arastirmax.com